Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2012
11/29/2012WO2012159456A1 Cdc42 inhibitor and uses thereof
11/29/2012WO2012159215A1 Compositions and methods for efficacious and safe delivery of sirna using specific chitosan-based nanocomplexes
11/29/2012WO2012159197A1 Drug delivery agents comprising cyclodextrin covalently linked to a gemini surfactant, and pharmaceutical compositions comprising the same
11/29/2012WO2012138857A9 Methods and materials for reducing supression of immune function
11/29/2012WO2012135757A3 Methods for treating cancer
11/29/2012WO2012135714A3 Serine biosynthesis pathway inhibition for treatment of cancer
11/29/2012WO2012125623A3 Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
11/29/2012WO2012118349A3 Differentiation and proliferation method for natural killer cells from cd14-positive monocytes
11/29/2012WO2012111025A4 1,2,3-triazole containing artemisinin compounds and process for preparation thereof
11/29/2012WO2012102937A3 Benz imidazole compounds that expand hematopoietic stem cells
11/29/2012WO2012102521A3 Human anti-cd23 fab antibody and a pharmaceutical composition for treating tumours comprising same
11/29/2012WO2012093920A3 Composition including white morning glory extract for treating leukemia
11/29/2012US20120304319 Tox3 as a biomarker for breast cancer
11/29/2012US20120304318 Cancer diagnosis and treatment
11/29/2012US20120302819 Treatment of cancer or tumors induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternative magnetic field
11/29/2012US20120302816 Therapeutic compositions and methods for targeted delivery of active agents
11/29/2012US20120302739 Biological products
11/29/2012US20120302650 Insulin-Like Growth Factor 1 Receptor (IGF1R) Protein SRM/MRM Assay
11/29/2012US20120302632 Dietary control of arachidonic acid metabolism
11/29/2012US20120302630 Na/K-ATPase Ligands, Ouabain Antagonists, Assays and Uses Thereof
11/29/2012US20120302629 Biomarkers for gossypol chemotherapy and methods of treating disease
11/29/2012US20120302625 Supercoiled minicircle dna for gene therapy applications
11/29/2012US20120302620 Novel pyrone-indole derivatives and process for their preparation
11/29/2012US20120302613 Novel antibiotics
11/29/2012US20120302609 Pyrazolines for the Modulation of PKM2
11/29/2012US20120302607 C4-substituted alpha-keto oxazoles
11/29/2012US20120302605 3-deutero-pomalidomide
11/29/2012US20120302599 KAT ll INHIBITORS
11/29/2012US20120302587 Rho-kinase inhibitors
11/29/2012US20120302584 Novel salts forms of pyrimidin-5-yl acetic acid derivative
11/29/2012US20120302582 Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer
11/29/2012US20120302581 Methods and Compositions for the Treatment of RAS Associated Disorders
11/29/2012US20120302579 Cancer treatment method
11/29/2012US20120302578 Aminooxazole Inhibitors of Cyclin Dependent Kinases
11/29/2012US20120302577 Treatment of gist with masitinib
11/29/2012US20120302576 Ampk modulators
11/29/2012US20120302573 Methods of inhibiting pro matrix metalloproteinase activation
11/29/2012US20120302572 Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
11/29/2012US20120302571 CRYSTALLINE FORMS OF (S)-1-(4-(5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)PYRROLO[1,2-f][1,2,4]TRIAZIN-2-YL)-N-(6-FLUOROPYRIDIN-3-YL)-2-METHYLPYRROLIDINE-2-CARBOXAMIDE
11/29/2012US20120302570 Heterocyclic oxime compounds
11/29/2012US20120302569 Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
11/29/2012US20120302567 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
11/29/2012US20120302563 Substituted norindenoisoquinolines, syntheses thereof, and methods of use
11/29/2012US20120302561 Compounds, Formulations, and Methods of Protein Kinase C Inhibition
11/29/2012US20120302557 Biologically active methylene blue derivatives
11/29/2012US20120302551 Thiolactams and uses thereof
11/29/2012US20120302550 Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
11/29/2012US20120302545 Method of Using PI3K and MEK Modulators
11/29/2012US20120302544 Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators
11/29/2012US20120302541 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
11/29/2012US20120302539 Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
11/29/2012US20120302530 23-hydroxy-betulinic acid derivatives, preparation methods and uses thereof
11/29/2012US20120302529 Method of treating actinic keratosis and basal cell carcinoma
11/29/2012US20120302524 1,3,4-oxadiazole-2-carboxamide compound
11/29/2012US20120302523 Endoperoxides and methods of photocatalytically synthesizing endoperoxides
11/29/2012US20120302520 Gemcitabine combination therapy
11/29/2012US20120302518 Polymorphic Form Of N-(S)-(3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-6-Methoxyphenyl)-1-(2,3-Dihydroxypropyl)Cyclopropane-1-Sulfonamide And Uses Thereof
11/29/2012US20120302514 Glycoconjugates and methods
11/29/2012US20120302511 Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer
11/29/2012US20120302510 Histone deacetylases, and uses related thereto
11/29/2012US20120302509 Compositions and methods to prevent cancer with cupredoxins
11/29/2012US20120302508 Sustained-release formulation
11/29/2012US20120302506 Maspin-based treatment and prevention of cancer
11/29/2012US20120302505 Cyclodextrin-based polymers for therapeutic delivery
11/29/2012US20120302503 PEPTIDES FOR PREVENTING OR TREATING A DISEASE OR DISORDER ASSOCIATED WITH CBP OR p300 MISREGULATION, AND METHODS FOR USE AND IDENTIFICATION THEREOF
11/29/2012US20120302500 Use of somatostatin analogs in meningioma
11/29/2012US20120302498 Insulin like peptides
11/29/2012US20120301537 LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF
11/29/2012US20120301512 Tetrary Gene Delivery System for Gene Therapy and Methods of Its Use
11/29/2012US20120301509 Boldline compounds for promoting bone growth
11/29/2012US20120301506 Oncolytic Virus as an Inducer for Innate Antitumor Immunity
11/29/2012US20120301499 Packaging of Immunostimulatory Substances into Virus-Like Particles: Method of Preparation and Use
11/29/2012US20120301490 Immunoconjugates, compositions for making them, and methods of making and use
11/29/2012US20120301489 Jagged-Binding Agents and Uses Thereof
11/29/2012US20120301488 Anti-cd40 antibodies and methods of use
11/29/2012US20120301477 USE OF CCR9, CCL25/TECK, AND INTEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE
11/29/2012US20120301476 Pharmaceutical composition for treating and/or preventing cancer
11/29/2012US20120301475 Novel heparanase splice variant
11/29/2012US20120301472 Reagents and treatment methods for autoimmune diseases
11/29/2012US20120301471 Pharmaceutical composition for treating and/or preventing cancer
11/29/2012US20120301468 Anti-mn antibodies and methods of using same
11/29/2012US20120301463 Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
11/29/2012US20120301459 Combination therapy of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc)
11/29/2012US20120301453 Inhibiting integrin receptor binding with non-native monomeric disintegrin or monomeric disintegrin domains
11/29/2012US20120301448 Th1-associated micrornas and their use for tumor immunotherapy
11/29/2012US20120301447 TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
11/29/2012US20120301443 Methods for developing endothelial cells from pluripotent cells and endothelial cells derived
11/29/2012US20120301431 Methods of treating a disease or condition associated with abnormal angiogenesis
11/29/2012US20120301425 Novel antitumoral use of cabazitaxel
11/29/2012US20120301424 Cyclodextrin-based polymers for therapeutics delivery
11/29/2012US20120301396 Radioimmunoconjugates and uses thereof
11/29/2012US20120301394 Targeting and in vivo imaging of tumor-associated macrophages
11/29/2012US20120301393 Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
11/29/2012DE102006007309B4 Verbessertes Verfahren zur Herstellung von Temozolomid An improved process for the preparation of Temozolomide
11/29/2012CA2837346A1 Soluble protein cd5 or cd6 for the treatment of cancer or tumor or for use as an adjuvant
11/29/2012CA2837327A1 Immunoconjugates, compositions containing them, and methods of making and use
11/29/2012CA2837170A1 Modular transport platform for targeted delivery of therapeutic agents
11/29/2012CA2836873A1 Deimmunized serum-binding domains and their use for extending serum half-life
11/29/2012CA2836865A1 Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
11/29/2012CA2836831A1 Pharmaceutical composition
1 ... 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 ... 2211